

[2, 24, 25, 32].

),

[3, 25].

[3, 24, 34].

[1, 17].

[24,

25].

[3, 26, 27].

[18, 20].

[2, 7, 25, 27].

" (the post-infectious chronic fatigue syndrome) [32, 34].

[17, 32, 34].

3-4 [3, 32].

:  
 " ( 0102U003362) "  
 [2, 4, 5, 19, 28, 29]. " ( 0108U009463).  
 [13, 21, 30].  
 64  
 29 (45,3%) 35  
 [4, 19, 29]. (54,7%) 29 50  
 32  
 25  
 4-6  
 [6].  
 [31]. ( ), ( UA6909/01/01  
 [16] UA6909/02/01  
 17.08.07 ., 483) [6].  
 [14, 16]. ( )  
 (Rad. Althaeae officinalis  
 (Flores Chamomillae officinalis L.), (Hb.  
 [15]. Equiseti arvensi L.), (Fol.  
 Juglandis regiae L.),  
 (Hb. Achilleae millefolii L.),  
 (Cortex Querci roburi L.)  
 (Hb. Taraxaci officinalis Weber) [35].  
 1  
 [31, 35]. (Rad. Althaeae) — 8  
 (Flor. Chamomillae) — 6  
 (Hb. Equiseti) — 10  
 (Fol. Juglandis) — 12  
 (Hb. Millefolii) — 4 (Cort. Quercus) —  
 [9, 10]. 4 (Hb. Taraxaci) — 4 [6,  
 31]. 100 29  
 (Rad. Althaeae) — 0,4 ;  
 (Flores Chamomillae) — 0,3 ; (Hb.  
 Equiseti) — 0,5 ; (Fol.  
 Juglandis) — 0,4 ; (Hb. Millefo-  
 lii) — 0,4 ; (Cort. Quercus) — 0,2 ;  
 (Hb. Taraxaci) — 0,4  
 ( ), : (16-19,5 .%),  
 [6, 35].  
 P  
 " ( ),

, , [14, 16].  
 , [13, 21, 30, 33].  
 , ( [25].  
 ( ) [23];  
 Staph. aureus, 505.  
 ( ) — [2, 3, 17].  
 ( ) — 1 ,  
 ( ) — , ( : 1).  
 100 ,  
 ( ) — 100 [8].  
 [11],  
 [12].  
 [7, 8].  
 . 1, , 22 (68,8%)  
 20 (62,5%)  
 12% 15%, 25  
 (78,1%) 23 (71,9%)  
 1,9-2,3; 18 (56,3%)  
 19 (59,4%)  
 9,3% - 10,9%.  
 17 (53,2%) 19  
 (59,4%)  
 12% 15%.  
 . 1,  
 . 2.  
 (

, %		12-15	16-19	20-23	24
	( =32)	22/68,8	7/21,8	3/9,4	0
	( =32)	20/62,5	8/25,0	4/12,5	0
		(26,5±2,0)%			
		1,2-1,8	1,9-2,3	2,4-3,2	3,5
	( =32)	4/12,5	25/78,1	3/9,4	0
	( =32)	4/12,5	23/71,9	5/15,6	0
		(4,0±0,15)			
, %		6,1-7,6	7,7-9,2	9,3-10,9	11-11,5
	( =32)	0	4/12,5	18/56,3	10/31,2
	( =32)	0	6/18,7	17/59,4	9/21,9
		(14,8±0,3)%			
, %		8-11	12-15	16-19	20
	( =32)	5/15,6	17/53,2	10/31,2	0
	( =32)	5/15,6	19/59,4	8/25,0	0
		(25,0±1,6)%			


: . 1-4 — , — % .

( ± )

		( =32)	( =32)	
, %	26,5±2,0	15,2±1,2**	15,8±1,1**	>0,05
	4,0±0,15	2,09±0,1**	2,16±0,12**	>0,05
, %	14,8±0,3	10,25±0,6*	10,1±0,5*	>0,05
, %	25,0±1,6	14,1±0,8***	13,9±0,7***	>0,05

: . 2 3 \* — <0,05, \*\* — <0,01, \*\*\* — <0,001;

1,7 , . 1  
15,2±1,2% 26,5±2,0% ( )  
( <0,01);  
15,8±1,1%, 1,68 , ,  
( <0,01).  
2,09±0,1, — / ,  
2,16±0,12, 1,9 , ,  
( <0,01) 1,85 ( <0,01) — .  
1,44 , ,  
(10,25±0,6)% ( <0,05) (14,8±0,3)%,  
— 1,47 , ,  
(10,1±0,5)% ( <0,05).  
1,77 ( <0,001) (14,1±0,8)% ( )  
(25,0±1,6)%, (13,9±0,7)%,  
1,8 [7, 8].  
( <0,001).



1.  $\therefore \bullet -$  ;  $\bullet -$  ;  $\bullet -$

[7, 22].

1,7 (24,9±1,3)%, ( >0,05).

1,9 — 3,9±0,06 ( >0,1);

1,44 (14,6±0,4)%, ( >0,05).

(14,8±0,3)% ( )

1,65 (23,3±1,4)%, ( >0,05).

1,18 , 1,34

1,39 2,8±0,05, ( <0,05).

1,3 ( <0,05) 1,43

(12,2±0,3)%, 1,2 ( <0,05),

1,2 ( <0,05).

1,3 (18,1±0,9)%, 1,29

( <0,05) 1,38 ( <0,05).

[23].

( ± )

		( =32)	( =32)	
, %	26,5±2,0	24,9±1,3	18,6±1,1*	<0,05
	4,0±0,15	3,9±0,06	2,8±0,05*	<0,05
, %	14,8±0,3	14,6±0,4	12,2±0,3*	<0,05
, %	25,0±1,6	23,3±1,4	18,1±0,9*	<0,05

. 2.

. 2,

.

,

21% —

15%      21%,

15-18%

19-

$$(3, 1\%),$$

(96,9%

22%      27%,

3,1      4,2.

2,0      3,0.


13,1%      15,0% .

11,0% - 13,0% ,

19,1% - 25,0% ,

(3, 1%)

4



. 2.

$$\vdots \quad \bullet \quad \text{---} \quad \vdots$$

1

(3, 1%)

, %		15-18	19-21	22-24	25-27
	( =32)	0	1/3,1	22/68,8	9/28,1
	( =32)	18/56,3	14/43,7	0	0
		(26,5±2,0)%			
		2,0-2,6	2,7-3,0	3,1-3,7	3,8-4,2
	( =32)	0	0	4/12,5	28/87,5
	( =32)	15/46,9	17/53,1	0	0
		(4,0±0,15)			
, %		11,0-12,0	12,1-13,0	13,1-14,0	14,1-15,0
	( =32)	0	0	12/37,5	20/62,5
	( =32)	14/43,8	17/53,1	1/3,1	0
		(14,8±0,3)%			
, %		15,0-17,0	17,1-19,0	19,1-22,0	22,1-25,0
	( =32)	0	0	15/46,9	17/53,1
	( =32)	7/21,9	24/75,0	1/3,1	0
		(25,0±1.6)%			



1. / 2005. - 256 .

2. /

0.1. // 1. - 3-10.

3. [3- ]. - ; 2006. - 482 .

4. / 2006. - 2. - 11-14.

5. /

1. : [" 2007. - 148-150.

6. 483 17.08.07 .

7. /

B. : 2006. - 528 .

8. / 2000. - 806 .

9. /

2009. - 8 (94).

C. 135-147.

10. / 2009. - 12, 6. - 107-110.

11. / 2000. - 320 .

12. / 2002. - 160 .

13. / 1990. - 408-409.

14. in vitro / 2005. - 3. - 74-76.

15. / 2006. - 3. - 37-39.

16. - / 2001. - 1. - 87-88.

17. / 1997. - 3 (4). - 11-12.

18. / 1997. - 3. - 33-35.

19. 64277 , 7 61 35/78, 61 31/695 / 2003043756. 23.04.2003. 16.02.2004. - 2.

20. / 1996. - 1-2. - 3-6.

21. / 2000. - 976 .

22. / 1995. - 3. - 44-48.

23. / 1990. - 9. - 27-29.

24. / 1998. - 1. - 69-81.

25. / 1998. - 1(16). - 46-62.

26. / 1998. - 2 (17). - 95-102.

27. / 1999. - 2. - 9-14.

28. / 2003. - 6, 4. - 164-167.

29. / 2007. - 2. - 16-22.

30. (La Sante par les plantes)/ [ ]. - " , 2004. - 350 .



31. . . / . . // . . . . - 2008. - 3(65). - . 1-13.
32. Buchwald D. *The post-infectious chronic fatigue syndrome: laboratory abnormalities* / D. Buchwald // *Epstein-Barr Virus and Human disease*. - NY: Humana Press, 1989. - P. 419-427.
33. Pengelly A. *The constituents of medicinal plants. An introduction to the chemistry and therapeutics of herbal medicines* /A. Pengelly. - Sunflower herbas, 2006. - 105 p.
34. *Immunological abnormalities in the chronic fatigue syndrome*/A.R. Lloyd, D. Wakiefeld, C.R. Boughton, J.M. Dwyer// *Med. J. Australia*. - 1984. - V. 151 (30). - P. 122-124.
35. Wagner H. *Expert report. In: Tonsilgon-N Coated Tablets. Part III and IV. File1. Pharmacological and toxicological documentation and Postmarketing surveillance studies and experience reports* / H. Wagner. Bionorica AG, Germany, 2000. - P. 1-30.
36. Wiart C. *Medicinal plants of Asia and Pacific*/C. Wiart. - Taylor&Francis Group, 2006. - 295 p.

30.03.2010

616.9(035).3:638.1:658.381

. . , . . , . . , . .

: , , ,

( ) ( ).

. . , . . , . . , . .

: ,

, ,

( )

( ).

T.P. Garnik, V.M. Frolov, N.A. Peresadin, I.V. Bilousova

# **MODERN COMBINED PHYTOPREPARATION IMUPRET INFLUENCE ON THE MACROPHAGE PHAGOCYtic SYSTEM OF THE PATIENTS WITH CHRONIC FATIGUE SYNDROME**

**Key words:** chronic fatigue syndrome, macrophage phagocytic system, imupret, treatment

The influence of modern combined phytopreparation imupret on the macrophage phagocytic system (MPS) of the patients with chronic fatigue syndrome (CFS) was studied. The positive imupret influence on MPS parameters and the clinical picture of disease was detected, that could be the reason for application phytopreparation in the treatment of the patients with CFS.